Compare Gilead Sciences, Inc. (GILD) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zeta Global Holdings Corp — how do they compare? Gilead Sciences, Inc. trades at $133.15 (market cap $163.51B), while Zeta Global Holdings Corp trades at $21.73 (market cap $5.59B). The key difference: Gilead Sciences, Inc. is far larger — about 29.3× Zeta Global Holdings Corp's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| GILD | ZETA | |
|---|---|---|
Market Cap | $163.51B | $5.59B |
Sector | Health | Technology |
52-Week High | $155.80 | $25.24 |
52-Week Low | $108.22 | $14.55 |
Enterprise Value | $178.05B | $5.49B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
ZETA stock trades at $21.335, down 5.3% over 24 hours, with technical indicators showing a bullish trend. The company reported strong revenue growth to $1.3 billion in 2025 but remains unprofitable with a net loss of $31.51 million. Recent strategic partnerships with Palantir, OpenAI, and Snowflake highlight Zeta's pivot toward AI infrastructure, driving positive analyst sentiment with 11 buy ratings and a $27.50 consensus price target.
ZETA presents a growth opportunity through AI adoption and enterprise expansion, but faces risks from negative cash flow and margin pressure. The stock's 29% upside to consensus target suggests potential, though profitability challenges and competitive threats require careful monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
